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Abstract 
Anophthalmia, microphthalmia and coloboma are a genetically heterogeneous spectrum 
of developmental eye disorders and affect around 30 per 100,000 live births. OLFM2 
encodes a secreted glycoprotein belonging to the noelin family of olfactomedin domain-
containing proteins that modulate the timing of neuronal differentiation during 
development. OLFM2 SNPs have been associated with open angle glaucoma in a case-
control study, and knockdown of Olfm2 in zebrafish results in reduced eye size. From a 
cohort of 258 individuals with developmental eye anomalies, we identified two with 
heterozygous variants in OLFM2: an individual with bilateral microphthalmia carrying a 
de novo 19p13.2 microdeletion involving OLFM2, and a second individual with unilateral 
microphthalmia and contralateral coloboma who had a novel single base change in the 
5’ untranslated region. Dual luciferase assays demonstrated that the latter variant 
causes a significant decrease in expression of OLFM2. Furthermore, in situ hybridisation 
experiments using human developmental tissue revealed expression in relevant 
structures, including the lens vesicle and optic cup. Our study indicates that OLFM2 is 
likely to be important in mammalian eye development and disease and should be 
considered as a gene for human ocular anomalies. 
 
Key words: OLFM2, anophthalmia, microphthalmia, coloboma, eye abnormalities, 5’ 
untranslated regions 
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Introduction 
Developmental eye anomalies, including anophthalmia, microphthalmia and coloboma 
(AMC) are a genetically heterogeneous group of disorders affecting around 30 per 
100,000 live births (Campbell et al., 2002). A rapidly growing number of genes have 
been identified for these anomalies, including SOX2 Fantes et al., 2003), OTX2 (Ragge et 
al., 2005) and BMP4 (Bakrania et al., 2008). Following the identification of a de novo 
19p13.2 microdeletion involving OLFM2 in an individual with bilateral microphthalmia, 
we investigated the role of this gene in developmental eye disorders. 
 
Single nucleotide polymorphisms (SNPs) in OLFM2 have been previously associated with 
open angle glaucoma (Funayama et al., 2006). OLFM2 has a 31% homology to MYOC 
(Myocilin), mutations of which account for 3-4% of primary open angle glaucoma and a 
significant proportion of juvenile open angle glaucoma (Mukhopadhyay et al., 2004). 
 
OLFM2 encodes a secreted glycoprotein belonging to the noelin family of olfactomedin 
domain-containing proteins that modulate the timing of neuronal differentiation during 
development (Gautier et al., 2009; Tomarev and Nakaya, 2009). OLFM2 is present in the 
nucleus and is predicted to contain a DNA binding domain and may play a role as a 
transcriptional coactivator (Shi et al., 2014). It is expressed in human (Mukhopadhyay et 
al., 2004), mouse (Sultana et al., 2011) and zebrafish eyes, zebrafish knockdowns 
exhibiting an average 24% decrease in eye area (Lee et al., 2008). This reduction is 
possibly mediated by decreased expression of Pax6, which is observed in zebrafish 
Olfm2 knockdowns (Lee et al., 2008). Heterozygous mutations in PAX6 cause aniridia, 
Peters’ anomaly, foveal hypoplasia, keratitis, cataract, coloboma and microphthalmia 
(OMIM #607108). OLFM2 may play a role in TGFβ signaling, which includes BMP4, 
during early eye development since OLFM2 expression has been shown to increase after 
TGFβ induction in human embryonic stem cell–derived mesenchymal cells (Shi et al., 
2014).  
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In addition to eye size, Olfm2 zebrafish knockdowns show altered nervous system 
development, including optic tectum, defects of the midbrain–hindbrain boundary, and 
altered axonal trajectories and extension (Lee et al., 2008). Interestingly, a distinct cutoff 
in OTX2 expression at the midbrain-hindbrain boundary is observed in the human 
embryo at CS14 (Ragge et al., 2005). Expression of Olfm2 is initially present in the entire 
zebrafish eye, becoming increasingly localised to the retinal ganglion cell layer as 
development progresses.   
 
Therefore, OLFM2 represents an excellent candidate gene for AMC. We describe an 
individual with bilateral microphthalmia and a de novo deletion on chromosome 
19p13.2 affecting OLFM2 and COL5A3. We screened OLFM2 for variants in 258 patients 
with developmental eye anomalies, identifying a second individual with a 5’ 
untranslated region (UTR) variant that decreases OLFM2 expression.  We demonstrate 
expression of OLFM2 in early human embryonic tissue including in the optic cup and 
lens vesicle. 
 
Materials and Methods 
Cohort Description 
A UK cohort with ocular anomalies, principally AMC, was recruited as part of a national 
‘Genetics of Eye and Brain anomalies’ study (REC study number 04/Q0104/129). Patients 
were screened by indication in known AMC genes. From this cohort 258 individuals 
without a genetic diagnosis were screened for variants in OLFM2. Of these, 32 
individuals had bilateral anophthalmia or unilateral anophthalmia with contralateral 
microphthalmia, 43 had bilateral microphthalmia (+/- coloboma), 146 had unilateral 
anophthalmia/microphthalmia (+/- contralateral defects), and 37 had other phenotypes, 
including anterior segment dysgenesis.  
 
Array-CGH 
6 
 
Array CGH was performed using the Agilent (USA) 44K oligonucleotide platform (design 
017457), as previously described (Ahn et al., 2010).  
 
Mutation Analysis 
All six coding exons of OLFM2 (NM_058164.3), the alternate first exon of 
NM_001304348.1, and flanking sequences were screened for mutations by high 
resolution melting curve analysis on a LightScanner (Idaho Technology) followed by 
Sanger sequencing of samples with aberrant melting curves (see Supplementary 
Methods and Supplementary Table 1 for detailed description) and sequence data 
analysed using CodonCode Aligner (CodonCode Corporation, Dedham, MA) or Chromas 
(Technelysium).  
 
Gene Panel Sequencing 
Next generation sequencing was performed for Case 1 using a custom designed Nextera 
based chemistry (Illumina) panel of 546 genes divided between 351 known eye disorder 
genes and 195 candidate genes, selected from animal models, pathophysiological 
pathways, and preliminary studies. Sequencing was performed using a custom designed 
Nextera based chemistry (Illumina) containing in excess of 10,225 probes targeting 
1,380,306bp. Sequence capture, sample barcoding and pre-enrichment sample pooling 
were performed according to manufacturer’s instructions (Illumina) and paired-end 
sequencing performed on the MiSeq sequencing platform (Illumina). Sequences were 
aligned to the reference human genome (UCSC hg19) using BWA-MEM (http://bio-
bwa.sourceforge.net/) and Novoalign v3.01.00 (Novocraft). The mean coverage was 
230x. Identified variants were filtered based on sequence quality, minor allele frequency 
and predicted effect. Filters were applied to remove variants with low quality 
('scThreshold': 0.94999999999999996, 'abThreshold': 0.001, 'minMapQual': 20, 
'minBaseQual': 20, 'badReadsThreshold': 20, 'hapScoreThreshold': 4). In addition, all 
synonymous variants and those with a frequency of at least 1% in the 1000 Genomes 
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Project database, or those which occurred in multiple patients run on this custom panel 
were removed. 
 
Transcription Factor Binding Bioinformatical Analysis 
Potential effects of the c.-57C>G OLFM2 5’ UTR variant were examined using the online 
program TFbind (http://tfbind.hgc.jp/) (Tsunoda and Takagi, 1999). Sequences 
containing the wildtype and variant alleles plus 15 bases of flanking sequencing were 
used as input data, and the program run using default settings. 
 
In Situ Hybridisation 
Nonradioactive RNA in situ hybridization was performed on human embryo sections at 
Carnegie Stages (CS) 15 and 17 as described elsewhere (Bakrania et al., 2008). Probes 
were designed to span the end of the coding region and part of the 3’ UTR of the OLFM2 
to bind all known splice variants and generated using primers 
GCTCGGCGGCCGCTTCACGTCATCAGCACCTCT and 
GCTCGGTCGACTCCATGCACTCAACTCCTGG. Human embryos were obtained from the 
MRC/Wellcome Trust Human Developmental Biology Resource, UCL, with full ethical 
approval.  
 
Cell Culture and cDNA Generation 
Y79 (human retinoblastoma) cells cultured in RPMI1640 media  supplemented with 
10mmol HEPES, 1mmol sodium pyruvate, 4.5g/L glucose, 2mmol L-glutamine, 20U/ml 
penicillin and 0.1mg/ml streptomycin and 20% fetal bovine serum (Sigma, Gillingham, 
UK). Cells were cultured at 37°C and 5% CO2. RNA was extracted using the RNeasy Mini 
Kit (Qiagen, UK). cDNA was generated using the QuantiTect Reverse Transcription kit 
(Qiagen).  
 
cDNA PCR  
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Primers were designed to span the unannotated 5’ UTR variant (Supplementary Table 
2). PCRs were performed using 1:10 diluted cDNA, 1X HotShotTM Mastermix (Cadama 
Medical), 10% v/v DMSO (Sigma) and 0.25μM of each primer in a final volume of 10μl. 
PCRs were 35 cycles and used a 55oC annealing temperature. OLFM2 expression was 
confirmed using a second PCR with primers for exon 6 that were also used for the 
LightScanner analysis (Supplementary Table 2). 
 
Dual Luciferase Assays 
Constructs were generated to incorporate the unannotated OLFM2 5’ UTR 
(NM_058164.3) variant from case 2 using primers 
(GCTCGGGTACCGCAACAAAGACTCGGAGCG and 
GCTCGGAGCTCCGTGAGCGGCCACATGAC) and cloned in the pGL3-Promoter vector 
(Promega). Vectors containing wild type and variant inserts were identified by Sanger 
sequencing, cultured overnight and DNA extracted.  
 
Transfections were performed using plasmids containing wild type, mutant or no insert. 
Normalisation was performed using pRL-TK plasmids (Promega). Per reaction, 2.5µg 
plasmid was diluted in 500µl Opti-MEM® I Reduced Serum Medium (Gibco) and 5µl 
PlusTM Reagent (Invitrogen), incubated at room temperature 15 minutes, 5µl 
Lipofectamine® LTX Reagent (Invitrogen) added and incubated for 15 minutes at room 
temperature. 500µl plasmid/lipofectamine mix was added to each well containing 3 x 
105 Y79 cells in 2ml RPMI1640 media (Sigma) and incubated at 37oC overnight. Cell 
lysates were obtained using Passive Lysis Buffer (PLB) (Promega) (manufacturer’s 
instructions), resuspended in 60µl PLB and stored at -80oC. Assays were performed using 
the Dual-Luciferase Reporter Assay System (Promega) (manufacturer’s instructions) and 
measured on a MicroBeta TriLux using Micro Beta Windows Workstation software 
(PerkinElmer). 
 
Results 
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Case 1  
A male infant was born to non-consanguineous Caucasian parents by normal delivery at 
41 weeks’ gestation weighing 3.046kg following an uneventful pregnancy. He had 
apparently isolated bilateral mild microphthalmia with cloudy vascularised sclerocornea. 
There was a reasonable view to a normal right disc and retina and no fundal view on the 
left. Cranial ultrasound examination was normal.  His initial growth was slow, along the 
2nd centile, length 25th centile, and head circumference 0.4th centile at 8 months of age. 
At 2 months of age, ocular ultrasound examination demonstrated the eyes had axial 
lengths of 15.1mm and 15.3mm (average for age 16.5mm).  Flash visual evoked 
potentials and electroretinograms were elicited from both left and right eyes. He 
developed a mild bilateral ptosis, early hearing problems and had narrow ear canals. His 
speech was delayed initially. At six years-of-age, his height was 107cm (2nd centile), 
weight 16kg (2nd centile) and head circumference 49 cm (0.4th centile). He had a 
relatively flat face with prominent chin and paucity of facial movements, small teeth, 
and unusual low set ears with slightly tilted earlobes and a bifid uvula.  His cognitive 
abilities appear to be normal, considering his visual impairment.   
 
Array CGH analysis revealed a de novo 19p13.2 microdeletion of between 46kb 
(chr19:9,913,222–9,959,613) and 81kb (chr19:9,896,892–9,978,107) (GRCh38/hg38) 
partially involving OLFM2 and COL5A3. The minimal deleted region is predicted to 
remove the first exon of two splice forms of OLFM2 (NM_058164.3 and 
NM_001304347.1) and part of the 3’ UTR of the final exon of COL5A3. In contrast, while 
the maximal deleted region is predicted to affect the same two exons of OLFM2, it also 
removes the final 26 exons of COL5A3 (Figure 1a).  Long range PCR across the region 
failed to generate a product (data not shown). G-banded chromosome analysis detected 
a de novo balanced reciprocal translocation between chromosomes 3 and 13 
(46,XY,t(3;13)(p23;q32)dn), detailed array CGH did not reveal any copy number variation 
in the regions involved in the translocation.  Parental karyotyping was normal and 
targeted aCGH of the deleted region showed no copy number variation. As the 
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translocation was balanced, the deletion was considered more likely to be relevant to 
ocular phenotype. In addition, after panel sequencing of 546 known and candidate eye 
development genes using a new purpose designed gene panel, Case 1 was found to be 
heterozygous for a variant (rs143247685, NM_004380.2: c.2728A>G, p.Thr910Ala) in 
CREBBP, alterations in which can cause Rubenstein-Taybi syndrome 1. However, as this 
is a known polymorphism with a population frequency of 0.226%, is not located within a 
functional domain of the gene and affects a non-conserved amino acid, it was deemed 
unlikely to affect the phenotype. No other plausible pathogenic variants were identified. 
 
As OLFM2 is expressed in the human eye, associated with glaucoma, and zebrafish 
knockdowns demonstrate microphthalmia, with no comparable reports for COL5A3 
suggesting a role in developmental eye anomalies, we prioritised OLFM2 and screened it 
for variants in our patient cohort.  
 
Case 2  
Case 2 is a male with unilateral microphthalmia with a unilateral cyst affecting the same 
eye and a contralateral coloboma, born to non-consanguineous parents at full term by 
normal delivery. His birth weight was 2.89kg. He is registered blind, has normal growth 
and cognitive development, and no other medical issues.  No causal variants were 
identified in SOX2 (Bakrania et al. 2007), OTX2 (Ragge et a., 2005), SHH (Bakrania et al. 
2010), FOXE3 (Iseri et al., 2009), BMP4 (Bakrania et al., 2008) or BMP7 (Wyatt et al., 
2010) via a combination of Sanger sequencing, fluorescence in situ hybridisation (FISH) 
and Multiplex Ligation-dependent Probe Amplification (MLPA) analysis (data not 
shown), and his chromosome analysis was normal. We identified a novel single base 
substitution of c.-57C>G in the 5’ UTR of OLFM2 (see below). 
 
Mutation analysis 
OLFM2 is located on chr19:9,853,718-9,936,552 (GRCh38/hg38), spans 82,835bp and 
comprises six exons. It has three splice forms with alternate first exons of 2019bp 
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(NM_058164.3), 1692bp (NM_001304348.1) and 1993bp (NM_001304347.1) encoding 
proteins of 454, 376 and 478 amino acids, respectively. A cohort of 258 patients were 
screened for variations in the exons and flanking intronic sequences, except 
NM_001304347.1 exon 1 (no working assay). We identified ten annotated variants, 
none reported pathogenic (ClinVar database); rs143959085, rs201189277, rs79341807, 
rs200752028, rs116666369, rs544945664, rs2303100, rs11556087, rs11556088, 
rs34961482 (Supplementary Table 3). Of these, one was intronic (rs116666369), four 
were synonymous (rs79341807, rs11556088, rs200752028, rs3496148). One variant was 
in the 5’ UTR (rs544945664), but due to a minor allele frequency nearing 0.01, it was 
considered unlikely to have a pathogenic role. The remaining four variants were 
missense changes. However, rs2303100 and rs11556087 have minor allele frequencies 
greater than 0.01 (dbSNP147). In addition, while the minor alleles for rs201189277 and 
rs143959085 are rare, they are not predicted damaging by SIFT (http://sift.jcvi.org/) (Ng 
and Henikoff 2003) or PolyPhen (,http://genetics.bwh.harvard.edu/pph/) (Adzhubei et 
al. 2010) and are in regions of limited conservation. rs201189277 was present in one 
individual  with unilateral anophthalmia, now deceased, for whom parental DNA was 
unavailable. rs143959085 was identified in one individual with anophthalmia with 
contralateral normal eye, bronchiectasis, congenital heart disease, skeletal problems, 
undescended testes, umbilical hernia, inguinal hernia, and polydactyly of both hands, 
but was inherited from the asymptomatic father. Therefore, these variants were 
considered unlikely to contribute to the patient phenotypes. 
 
A previously unreported 5’ UTR c.-57C>G variant (chr19:9,936,451 [GRCh38/hg38]) was 
identified in Case 2, validated by Sanger sequencing, and inherited from his 
asymptomatic mother.  Analysis using TFbind (http://tfbind.hgc.jp/) (Tsunoda and 
Takagi, 1999) identified potential effects on transcription factor binding, including 
General Transcription Factor IIIA, Sp1 Transcription Factor and Early Growth Response 3.  
 
Luciferase Assays 
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OLFM2 expression in Y79 cells was confirmed by PCR from cDNA. Two sets of triplicate 
transfection reactions were performed using plasmids containing wild type, mutant or 
no inserts, and normalised to Renilla luciferase expression from a co-transfected pRL-TK 
plasmid containing no insert. A 21% decrease in expression from the mutant insert 
relative to wild type was identified (2 tailed unpaired t-test P = 0.0209) (Figure 1b). 
 
In Situ Hybridisations 
In situ hybridisations were performed on transverse sections of human CS15 and CS17 
brain and eye tissue. At CS15 OLFM2 expression was observed in structures including 
the rhombencephalon, vagus, tissue surrounding the adenohypophyseal pouch, 
hypothalamus, otic vesicle, lens vesicle and optic cup.  At CS17 we observed expression 
in the lens vesicle, cerebral vesicle, spinal ganglion, ventricular zone, intermediate zone, 
marginal zone and the tissue surrounding the diencephalic superventricle (Figure 2a-m). 
 
Discussion 
The identification of a de novo deletion affecting OLFM2 and COL5A3 in a boy with 
bilateral microphthalmia and sclerocornea led to a positional candidate gene approach 
to investigate OLFM2 in human eye development. We identified a further case with 
unilateral microphthalmia plus cyst and contralateral coloboma with an unannotated 
mutation in the 5’ UTR of OLMF2, which significantly decreases expression of OLFM2 in 
vitro. OLFM2 expression was demonstrated in multiple regions of the developing human 
embryo, including the lens vesicle and optic cup, but also primitive hypothalamus-
pituitary axis, spinal ganglion and otic vesicle. 
 
Case 1 had a de novo deletion affecting OLFM2 and COL5A3. Although microdeletions 
spanning this region in other cases have been reported (Wong et al., 2007; Shaikh et al., 
2009), it is unknown whether affected individuals were screened for eye phenotypes. 
Given prior reports of the role of OLFM2 in developmental eye disease (Mukhopadhyay 
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et al., 2004; Funayama et al., 2006; Lee et al., 2008), we screened OLFM2 in our cohort 
of 258 patients with developmental eye anomalies. 
 
The unannotated heterozygous substitution in the 5’ UTR of OLFM2 in Case 2 was 
predicted to alter transcription factor binding, and demonstrated a 21% decrease in in 
vitro expression. The asymptomatic status of the carrier mother suggests this variant 
exhibits variable penetrance, often seen in eye development genes. The role of UTR and 
promoter variants in human disease is increasingly recognised. For example, a 5’ UTR 
substitution in PDE6H in a patient with cone dystrophy increases PDE6H expression 
leading to 4-5 times more protein, possibly resulting in cone degeneration by elevating 
cGMP in vivo (Piri et al., 2005). Zhou et al identified a novel heterozygous SOX2 3’ UTR 
variant in an individual with bilateral anophthalmia, suggesting this may affect 
expression (Zhou et al., 2008). Investigation of variants located within control regions of 
developmental eye genes is likely to provide an important source of causal changes and 
aid delineation of eye gene networks. 
 
The potential contribution of Case 1’s deletion and Case 2’s unannotated variant to their 
phenotype is supported by the expression of OLFM2 in the developing human optic cup 
and lens vesicle. OLFM2 was also expressed in the developing ear, hypothalamic- 
pituitary axis, and other parts of brain and neural tube, which may partly explain narrow 
ear canals, and reduced growth observed in Case 1. This indicates that more highly 
penetrant OLFM2 variants may cause wide-ranging phenotypes and could be important 
for developmental disorders affecting other structures. Findings, including the bifid 
uvula, may relate to effects of COL5A3 since this is seen in other collagen genes (Mark et 
al., 2011). The relatively mild phenotype observed in Case 2 is consistent with the 
moderate effect of the variant on expression, and the modest reduction in eye size seen 
in zebrafish models (Lee et al., 2008). OLFM2 may function by regulating transcription as 
an enhancer via the TGFβ cascade in eye development (Shi et al., 2014) and by 
interaction with PAX6 (Lee et al., 2008). The TGFβ cascade has been implicated in eye 
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development (Lovicu et al., 2011), and PAX6 is a well-known control gene involved in 
this process (Hever et al., 2006). Thus alterations in expression caused by mutations may 
have cascading effects through these pathways. However, further variants within 
additional patient cohorts will be required to more accurately ascertain the range of 
phenotypes associated with changes in OLFM2. 
 
Our investigations have not excluded the role of the partial COL5A3 deletion 
contributing to the phenotype of Case 1, which includes a number of non-
ophthalmologic features. COL5A3 is closely related to COL5A1, which encodes a protein 
that forms a heterotrimer with COL5A1 and COL5A2 to generate one form of type V 
collagen. In the mouse embryo Col5a3 is primarily expressed in developing muscle and 
ligaments. In humans, COL5A3 is expressed in multiple tissues in both the adult and 
fetus, including multiple regions of the brain, while in 15.5dpc mice it is primarily 
expressed in muscle, ligaments and connective tissues (Imamura et al., 2000). During 
zebrafish development, Col5a3 is expressed in the notochord, as well as the retinal 
pigment epithelium, and mesenchyme cells of the eye and lens (Fang et al., 2010). 
Therefore, it is possible that the loss of the 3’ end of COL5A3 may contribute to the eye 
phenotype of Case 1. In addition, both COL5A1 and COL5A2 (but not COL5A3) have been 
implicated in classical Ehlers-Danlos syndrome, a complex disorder with multiple 
phenotypes involving the connective tissue, including skin, eyes, ears and teeth 
(Imamura et al., 2000; Hoffman et al. 2008) (OMIM #130000). This is of particular 
interest, as the Case 1 phenotype includes small ears and low set ears with slightly tilted 
earlobes. Therefore, further investigation of the role of this gene is warranted.  
 
In conclusion, we identify genetic variants of OLFM2 in two individuals with 
developmental eye disorders and reveal expression in the developing human eye, 
indicating that it is an important candidate for screening in other cohorts with 
developmental eye anomalies, and highlighting the importance of screening control 
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regions both to identify causal variants and to aid understanding of the networks of 
genes involved in eye development. 
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Figure Legends 
Figure 1: Effect of unannotated variants identified within OLFM2. a. Copy number 
variant in Case 1. b. Dual-luciferase reporter assay showing reduced expression driven 
from the novel OLFM2 5’ UTR variant c.-57C>G (chr19:9,936,451 [GRCh38/hg38]) 
relative to the wild type sequence. The Renilla luciferase expressing plasmid pRL-TK was 
co-transfected as a control. 
 
Figure 2: OLFM2 in situ hybridisation studies in the developing human. a, b: In situ 
hybridisations of coronal sections of a CS15 human fetus using OLFM2 antisense (a) and 
sense (negative control) (b) probes reveal expression in structures including the 
diencephalic superventricle (future third ventricle), optic cup, lens vesicle, Rathke’s 
pouch (future pituitary), trigeminal ganglion, otic vesicle, vagus nerve and 
rhombencephalon (future fourth ventricle). Highest expression was observed in the 
dorsal portion of the rhombencephalon. c, d: In situ hybridisations of coronal sagittal 
sections of a CS17 human fetus using OLFM2 antisense (c) and sense (negative control) 
(d) show expression of OLFM2 in diencephalic superventricle, optic cup, lens vesicle, 
neural tube, and in the dorsal root ganglia. e-j: High magnification images of OLFM2 
expression in the CS15 human fetus in multiple structures: (e) lens vesicle and retinal 
ganglion cell layer, (f) trigeminal ganglion, (g) vagus nerve, (h) vestibular cochlear 
ganglion and otic vesicle, (i) diencephalic superventricle and Rathke’s pouch, and (j) 
rhombencephalon. k-m: High magnification images of OLFM2 expression in the CS17 
human fetus in multiple structures: (k) lens vesicle and retinal ganglion cell layer, (l) 
neural tube and differentiating neurons, and (m) the dorsal root ganglia. Abbreviations: 
DG = dorsal root ganglion; DN = differentiating neurons of the neural tube; DS = 
diencephalic superventricle; LV = lens vesicle; NT = neural tube; OC = optic cup; OV = 
otic vesicle; R = rhombencephalon; RG = retinal ganglion cell layer; RP = Rathke’s pouch; 
TG = trigeminal ganglion; V = vagus nerve; VCG = vestibular cochlear ganglion. 
 
